      Document 0165
 DOCN  DRG0165
 UNIQUE IDENTIFIER        DRG-0082
 NAME OF SUBSTANCE        Liposyn III [Abbott Laboratories Drug
                          Information Packet, Oct 1985]
 REGISTRY NUMBER          79468-94-3
 SYNONYMS                 Intravenous fat emulsion 2 percent [Abbott
                          Laboratories Drug Information Packet, Oct
                          1985]
 SYNONYMS                 Safflower oil and soybean oil [Abbott
                          Laboratories Drug Information Packet, Oct
                          1985]
 PROTOCOL ID NUMBERS      FDA 041A
 PROTOCOL ID NUMBERS      FDA 041B
 SECONDARY SOURCE ID      DRG
 PHARMACOLOGICAL ACTION   MODE OF ACTION: Liposyn III is a 2%
                          intravenous fat emulsion solution,
                          manufactured exactly the same as Liposyn II,
                          which is a 20% solution. Refer to the record
                          for Liposyn II for further information.
                          [Abbott Laboratories Drug Information Packet,
                          Oct 1985]
 DISEASES STUDIED/TREATED Nutritional support [FDA 041A] [FDA 041B]
 CLASSIFICATION CODE      Nutritional support [FDA 41A]
 OTHER MAJOR USES         Is indicated as a source of calories for
                          patients requiring parenteral nutrition
                          [Abbott Laboratories Drug Information Packet,
                          Oct 1985]
 CHEMICAL/PHYSICAL DATA   DRUG DESCRIPTION: Liposyn III is a 2%
                          solution of the same materials as Liposyn II.
                          Refer to the record for Liposyn II for
                          further information [Abbott Laboratories Drug
                          Information Packet, Oct 1985] [AHFS Drug
                          Information 1995]
 SUBSTANCE DELIVERY DATA  DOSAGE FORM: Refer to record for Liposyn II.
                          [Abbott Laboratories Drug Information Packet,
                          Oct 1985]
 SUBSTANCE DELIVERY DATA  MODE OF DELIVERY: Refer to record for Liposyn
                          II. [Abbott Laboratories Drug Information
                          Packet, Oct 1985]
 SUBSTANCE DELIVERY DATA  STORAGE INSTRUCTIONS: Refer to record for
                          Liposyn II. [Abbott Laboratories Drug
                          Information Packet, Oct 1985]
 MANUFACTURERS            Abbott
 REFERENCES               Saladino CF, Kosacolsky-Singer C, Fox R,
                          Nethala V, Feffer SE, Jonas EA. The effect of
                          parenteral lipid emulsion-induced
                          hyperlipidemia on prostaglandin E1 modulation
                          of platelet function. Artery.
                          1993;20(6):303-13.
 REFERENCES               Singer P, Rubinstein A, Askanazi J, Calvelli
                          T, Lazarus T, Kirvela O, Katz DP. Clinical
                          and immunologic effects of lipid-based
                          parenteral nutrition in AIDS [see comments].
                          JPEN J Parenter Enteral Nutr. 1992
                          Mar-Apr;16(2):165-7.
 REFERENCES               McLeod HL, McGuire TR, Yee GC. Stability of
                          cyclosporine in dextrose 5%, NaCl 0.9%,
                          dextrose/amino acid solution, and lipid
                          emulsion. Ann Pharmacother. 1992
                          Feb;26(2):172-5.
 REFERENCES               Update: October 1989 guidelines for
                          nutritional support in AIDS. Task Force on
                          Nutrition in AIDS. J Arkansas Med Soc. 1989
                          Nov;86(6):219-28.
 REFERENCES               Crocker KS. Gastrointestinal manifestations
                          of the acquired immunodeficiency syndrome.
                          Nurs Clin North Am. 1989 Jun;24(2):395-406.
 REFERENCES               Probart CK. Guidelines for nutritional
                          support in AIDS. J Sch Health. 1989
                          Apr;59(4):170-1.
 ENTRY MONTH              9003
 LAST REVISION DATE       960314
 

SOURCE: National Library of Medicine, Bethesda, MD.  Distributed by AEGIS.
